Lodoxamide
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Lodoxamide
Lodoxamide: Known uses and market status in Canada
Summary
The TxGNN deep-learning model (score ≥ 0.99) produced candidates for Lodoxamide, but every candidate that can be traced to a source is already a known use. There is therefore currently no new predicted indication for this drug. The single known use among the candidates is recorded as a knowledge graph relation, not as an approval.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| papillary conjunctivitis |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 00893560 | ALOMIDE | Valid |
Safety Considerations
- Drug Interactions: No drug-drug interaction records were found. One pharmacology record lists GPR35 as a target of lodoxamide (a target association, not a drug interaction).
Please refer to the package insert for other safety information, including warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.